Blog

Obagi Transformations: Kathy Hagquist

Kathy’s testimonial is another inspirational Obagi Nu Derm® transformation story that we are excited to share with our readers!

Like so many others, Kathy suffered with sun damage that manifested as freckles and sunspots. She wanted to diminish her hyperpigmentation, but wasn’t sure where to start.

Fortunately, her aesthetician introduced her to the Obagi Nu Derm system, and she hasn’t looked back since! During treatment, Kathy’s skin initially looked worse before it looked better, as it needed time to adjust to a new system of products with active ingredients.

However, after a few weeks, Kathy began to see noticeable results* and this motivated her to continue. And we are so glad she did!

Check out her inspirational story with before and after photos:

“My name is Kathy and I’m 54 years old. I met my aesthetician, Hillary, in November 2016. She recommended the Obagi Nu Derm system for my hyperpigmentation. As you can see in my before photos, I had freckles, sun spots, and sun damage.

I then started using the products for several months daily. Initially, there was some redness and peeling, and it took several weeks for my skin to adjust. As I adjusted to the products and I started to see results, it motivated me to keep going.

At month 3, I started to use ELASTIderm Eye Cream as well as Sun Shield TINT SPF 50, which I wear every day. At about month 4, I was using the Obagi Nu Derm products as maintenance, and that is what I’ve continued for the last 11 months.”

BEFORE: NOVEMBER 2016

AFTER: JULY 2017

*Individual results may vary.

Not available in select states including MA, MT, NH, NY, and TX, due to state regulations regarding the ability of physicians to dispense prescription drug products in their offices. For an effective, cosmetic, skin-brightening option, learn about the Obagi Nu-Derm FxTM system.

The safety and effectiveness of the Obagi Nu-Derm System beyond 24 weeks of use have not been established. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. See below for Important Safety Information about the Obagi Nu-Derm system.

IMPORTANT SAFETY INFORMATION FOR OBAGI NU-DERM CLEAR AND BLENDER®

(Contain prescription 4% hydroquinone)

CONTRAINDICATIONS:

People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS:

Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS):

Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

Find Obagi Products

Sign up to receive exclusive emails for first-look access to new Obagi products, expert skin care tips and advice, special promotions, and more!

All fields required

First Name *

Email *

Are you a U.S. Resident? *

Yes

No

Zip Code *

Obagi will never sell, rent, or share your personal information with any third parties for marketing purposes without your express permission. By submitting your information, you confirm you have read and agree with the terms of our Privacy Policy.

Stay Connected With Obagi

Obagi Premier Points®

Earn points every time you purchase participating Obagi products from your physician. Join today and redeem accumulated points for free Obagi products in the future. Terms and conditions apply. Download the app to see full terms and conditions.

Obagi Systems and Products are physician-dispensed and should be used only under the guidance of your skin care physician. Please be advised that certain products have limited distribution and may not be available in your area. Please contact your Obagi skin care physician for more information.

Important Safety Information for Obagi Nu-Derm Clear and Blender®

(contains 4% hydroquinone)

CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

CONTRAINDICATIONS:
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.